SK Pharmteco establishes advanced viral vector manufacturing facility in France

FRANCE—SK Pharmteco has announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France, marking a significant expansion in the company’s viral vector production capabilities.

 The facility is now fully operational and ready to support late-stage clinical trials and commercial viral vector programs at industrial scale.

The French Health Authority, ANSM, recently conducted a comprehensive inspection of the facility and granted approval for operations.

Following this regulatory milestone, the site has already produced its first batch using the company’s proprietary AAVelocity platform, demonstrating its readiness for client programs.

Eliminating the readiness gap

Joerg Ahlgrimm, CEO of SK Pharmteco, emphasised that the facility’s qualification represents a crucial milestone for the company and its partners.

He explained that the new site provides a fully inspected and approved environment that mirrors the company’s development workflows, effectively eliminating what he described as the traditional readiness gap in viral vector manufacturing.

Ahlgrimm highlighted that clients can now scale their programs seamlessly from preclinical stages through to commercial supply.

The facility enables this continuity by maintaining the same teams, platforms, and systems throughout the entire development journey, ensuring faster speed-to-market for cell and gene therapy products.

Purpose-built infrastructure

The new infrastructure has been specifically designed to deliver reproducibility and scale for viral vector manufacturing.

The facility houses two multiproduct and independent manufacturing suites, providing operational flexibility and risk mitigation for parallel client programs.

The site encompasses two independent viral vector production suites within a 5,000-square-meter purpose-built CGMP facility.

This specialized design supports scalable manufacturing processes while maintaining the stringent quality standards required for advanced therapy medicinal products.

Advanced production capacity

The facility features 12 single-use bioreactors ranging from 50 liters to 1,000 liters in capacity.

This equipment configuration provides a total installed upstream capacity of 5,000 liters, enabling the facility to handle diverse project requirements and batch sizes.

The site can produce up to 40 CGMP batches annually, supporting parallel processing for multiple client programs and ensuring reliable supply chains.

This capacity addresses growing demand for viral vector manufacturing services as more cell and gene therapies advance through clinical development.

Platform technology integration

SK pharmteco leverages its established platforms, AAVelocity and LentiSure, to ensure process consistency across different production scales.

The company ensures that processes running at clinical scale remain reliable and reproducible when scaled up to larger commercial volumes.

This approach significantly reduces technical and regulatory risks for cell and gene therapy developers who must demonstrate manufacturing consistency throughout product development.

The platform-based strategy enables smoother transitions between development phases while maintaining product quality attributes.

Addressing market challenges

The facility expansion directly addresses critical challenges currently facing the viral vector manufacturing market.

Regulatory confidence remains a primary concern for therapy developers, as manufacturing sites must demonstrate compliance with evolving guidance for advanced therapy medicinal products.

Operational continuity presents another significant pain point, as many developers struggle to maintain consistent processes when transferring manufacturing between facilities or scaling up production.

The new French facility tackles both issues by providing a validated, inspection-ready environment that supports programs from early clinical stages through commercial launch.

Ahlgrimm noted that the fully operational status of the Corbeil-Essonnes facility strengthens SK Pharmteco’s position as a partner capable of supporting the complete development lifecycle for viral vector-based therapies.